Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors

The synthesis of benzimidazole linked oxadiazole derivatives designed as potential EGFR and erbB2 receptor inhibitors with Anticancer and apoptotic activity were studied. Compounds 7a specifically inhibit EGFR and erbB2 receptor at 0.081 and 0.098 μM concentration. Some of the compounds showed strong, broad-spectrum antiproliferative activitiy when tested against five human Cancer cell lines. Compounds 7a and 7n were more cytotoxic than 5-fluorouracil against MCF-7 Cancer cell, with IC₅₀ values of 5.0 and 2.55 μM whereas, only 7a led to cell cycle arrest at G₂/M phase accompanied by an increase in Apoptosis. Compounds 7a and 7n showed normal architecture of myofibrils in cardiomyopathy study whereas only compound 7a showed nearly equal biochemical parameters (SGOT and SGPT) when compared to control. Molecular docking & 3D-QSAR studies were used to establish interactions of 7a and 7n within the active site of Enzyme for ATP binding site of kinase domain.

3D-QSAR studies; Anticancer; Apoptosis; Benzimidazole linked oxadiazole.